0
Abstract: Poster Presentations |

DATA FROM THE TOP TEN ENROLLING COUNTRIES CONTAINED IN THE PROGRESS (PROMOTING GLOBAL RESEARCH EXCELLENCE IN SEVERE SEPSIS) REGISTRY DEMONSTRATES VARIATIONS IN TREATMENT AND HIGH MORTALITY RATES FREE TO VIEW

Konrad Reinhart, *; Jean-Louis Vincent; Graham Ramsay; Claudio Martin; Eliezer Silva; Richard Beale; Frank M. Brunkhorst; Mitchell Levy; Gregory Martin; Mary Ann Turlo; Samiha Sarwat; Jonathan Janes
Author and Funding Information

Universitasklinikum Jena, Jena, Germany


Chest


Chest. 2005;128(4_MeetingAbstracts):377S. doi:10.1378/chest.128.4_MeetingAbstracts.377S-a
Text Size: A A A
Published online

Abstract

PURPOSE:  PROGRESS is an international, prospective, observational registry on severe sepsis patients in Intensive Care Units.

METHODS:  Patients diagnosed with severe sepsis (suspected on proven infection + >1 acute sepsis induced organ dysfunction[s]) were included; there were no exclusion criteria. Data were entered from participating institutions via secured website. An independent advisory committee governs PROGRESS. Software development and website maintenance are funded by Eli Lilly.

RESULTS:  Results As of 3/11/05 there were 11,925 patients in the registry with 8,456 from the top 10 enrolling countries. (Table #1).

CONCLUSION:  Management of severe sepsis varies across geographic regions and mortality rates are high. The similarity of ROC curves provides support for the validity of the database and are independent predictors of death despite these variations.

CLINICAL IMPLICATIONS:  More research is necessary to explore the reasons for differing patient management and outcomes. Germany n 1436Argentina n 1326Brazil n 921Canada n 889India n 841Malaysia n 684Australia n 679US n 671Mex n 516Philippines n 493ICU Mortality38%46%56%32%37%56%22%33%39%41%APACHE II (mean)27232324202421262224>2 OD90%75%93%na90%93%91%87%93%94%Vent use89%79%92%90%64%99%89%76%95%76%Vasopres.93%69%75%64%59%89%88%76%90%79%Fluid resuscitation95%86%94%na63%93%86%84%97%67%Albumin4.5%9%10%na37%29%53%19%32%14%Low dose steroids46%30%59%38%29%11%30%29%30%25%Renal replacement33%12%21%14%15%22%26%18%13%17%DroAA5%2%7%8%4%2%8%27%11%2%Unfx heparin*63%59%55%73%8%34%61%30%10%8%Low mole. Wt. Heparin*48%14%45%14%21%16%16%32%58%17%*

Sum may exceed 100% due to possibility of sequential treatment

DISCLOSURE:  Konrad Reinhart, Consultant fee, speaker bureau, advisory committee, etc. Speaker is a member of the PROGRESS advisory committee.

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543